The clinical trial of testosterone treatment in men with chronic kidney disease

This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).

The purpose of this research is to find out if JATENZO will help increase testosterone levels in men with hypogonadism and chronic kidney disease, determine if there is any improvement in testosterone levels, hemoglobin (red blood cells), muscle strength, lean mass and sexual function. The dug will be daily for 6 months. 

The clinical trial starts in March 15, 2022 and will continue throughout December 31, 2023.

Testosterone concentrations will be primary outcome measure. Testosterone concentrations in serum measured multiple times during the study.

For more details: https://ichgcp.net/clinical-trials-registry/NCT05249634.